Loading organizations...
§ Private Profile · 700 Main Street, North Cambridge, MA 02139, US
Biotechnology company developing gene therapies for monogenic diseases, focused on Alpha-1 Antitrypsin Deficiency and ALS.
Founded in 2017 by John Erbe, Christian Mueller, and Terence Flotte, Apic Bio is a Cambridge, Massachusetts biotechnology company developing adeno-associated virus gene therapies for rare genetic and neurological disorders. The organization utilizes its proprietary THRIVE platform to create treatments that simultaneously silence mutant genes and replace normal gene products in a single vector. Operating with six employees and generating approximately $8.6 million in annual revenue, the enterprise maintains a drug pipeline of four active preclinical and clinical programs targeting conditions like amyotrophic lateral sclerosis. The firm has raised $40 million in Series A financing from institutional investors including Morningside Ventures and the ALS Investment Fund to advance these experimental therapeutics. Originally established as a spinoff from the University of Massachusetts Medical School, the company successfully secured FDA clearance for its lead gene therapy candidate.
Apic Bio has raised $42.0M across 1 funding round.
Apic Bio has raised $42.0M in total across 1 funding round.
Apic Bio is a US-based biotechnology company headquartered in Cambridge, Massachusetts, specializing in gene therapy for rare genetic diseases, particularly neurological and liver disorders.[1][3][4][5] It develops novel treatments using its proprietary THRIVE™ platform, a modular dual-function vector system that silences harmful genes while replacing them with beneficial ones, targeting conditions like Huntington's disease, refractory temporal lobe epilepsy, ALS (including SOD1 and C9orf72 forms), Fabry disease, and Alpha-1 Antitrypsin Deficiency (A1AT).[1][2][7] The company serves patients with rare monogenic disorders, addressing unmet needs in undertreated areas through a pipeline including APB-101 (A1AT, IND stage), APB-102 (SOD1-ALS, licensed from uniQure in 2023), APB-103/104/105 (various ALS and A1AT indications, preclinical/discovery), and others like AMT-162.[1][7] Growth momentum includes strategic licensing deals and advancement of AAV-based therapies toward clinical stages.[1][7]
Apic Bio emerged as a pioneering gene therapy player focused on rare, monogenic disorders, though specific founding year and founders are not detailed in available sources.[3][4] The company's idea stems from leveraging a validated, modular technology platform—highlighted by the THRIVE™ system—to tackle severe diseases lacking effective treatments, with early emphasis on neurological conditions like ALS and epilepsy.[1][2][5] A pivotal moment came in January 2023 with a global licensing agreement for APB-102 (SOD1-ALS) from uniQure, validating its approach and expanding its pipeline.[1] This deal, alongside rebranding efforts emphasizing patient-centric innovation, marked early traction in a competitive biotech landscape.[2]
Apic Bio stands out in gene therapy through these key strengths:
Apic Bio rides the explosive growth in gene therapy for rare diseases, fueled by advances in AAV vectors and regulatory momentum (e.g., FDA approvals for similar therapies).[1][6][7] Timing is ideal amid rising investment in monogenic disorders, where modular platforms like THRIVE™ address limitations of first-generation therapies by enabling dual-action efficiency.[2] Market forces favoring it include surging demand for ALS and neurological treatments—underserved markets with few options—and biotech funding for "platform" companies that de-risk pipelines across indications.[3][5] It influences the ecosystem by advancing "first-in-class" options, potentially setting standards for dual-vector tech and inspiring cross-licensing in gene therapy.[1][2]
Apic Bio is poised for milestone progress, with near-term catalysts like IND filings for APB-101 and clinical entry for licensed assets like APB-102/AMT-162, potentially driving partnerships or funding rounds.[1][7] Shaping trends include AI-optimized vectors, expanded ALS approvals, and global access to rare disease therapies, amplifying its modular platform's scalability. Its influence could evolve from pipeline developer to ecosystem leader if THRIVE™ yields proof-of-concept data, transforming rare genetic diseases from life sentences to manageable conditions—echoing its core mission of revolutionary, hope-driven innovation.[2]
Apic Bio has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series A in January 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2019 | $42M Series A | Jason Dinges | ALS Investment Fund, A1atd Investors, The Alpha 1 Project | Announced |
Apic Bio has raised $42.0M in total across 1 funding round.
Apic Bio's investors include Jason Dinges, ALS Investment Fund, A1ATD Investors, The Alpha-1 Project.